Abstract
This investigation has been an ongoing, multistage evaluation of the pharmacokinetics, safety and efficacy of a factor VIII concentrate prepared through recombinant DNA technology. In vivo activity of the rFVIII has been comparable to that of pdFVIII including half life and in vivo recovery. Recombinant factor VIII is safe and effective for prophylaxis and treatment of hemophilic bleeding episodes. Efficacy of rFVIII appears comparable with that of pdFVIII concentrates. Infusions were well tolerated with infrequent adverse reactions. As with any new product, the verdict regarding induction of inhibitors to factor VIII awaits evaluation of sufficient numbers of patients and passage of adequate observation time.
Original language | English |
---|---|
Pages (from-to) | 47-51 |
Number of pages | 5 |
Journal | Seminars in Hematology |
Volume | 28 |
Issue number | 2 SUPPL. 1 |
State | Published - Apr 1991 |